ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Haematology series | MDS: spotlight on NAE inhibitors"
Episode Synopsis
Last week we discussed the array of therapeutic options in the pipeline for patients with MDS. Today we shine a spotlight on NAE inhibitors, the first of which recently received FDA breakthrough designation to bring it to the clinic faster. To answer our questions about the current data and future therapeutic use for this novel class of drugs, we welcome Dr Magnus Tobiasson, senior consultant in internal medicine and hematology at Karolinska University Hospital in Huddinge, Sweden.
References:
Swords, et al. Br J Haematol. 2015 (4):534-43
Zhu, et al. Genes (Basel). 2020; 11(9): E990
Majidi, et al. Blood. 2017; 130(1): 5298
Ades, et al. ASCO 2020. Abstract 7506
This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.
References:
Swords, et al. Br J Haematol. 2015 (4):534-43
Zhu, et al. Genes (Basel). 2020; 11(9): E990
Majidi, et al. Blood. 2017; 130(1): 5298
Ades, et al. ASCO 2020. Abstract 7506
This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.
More episodes of the podcast Oncology Knowledge into Practice Podcast
The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care
21/03/2023
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
23/09/2022
Tissue is Never the Issue
27/06/2022
Thyroid cancer: testing for biomarkers
01/04/2022
In God we trust